Nicorette, NicoDerm CQ Marketing Is Free From Conflict Of Interest – GSK
This article was originally published in The Tan Sheet
Executive Summary
No tobacco company "exerts any influence whatsoever" over the marketing of Nicorette gum and NicoDerm CQ transdermal patch smoking cessation products, according to GlaxoSmithKline
You may also be interested in...
Ariva Tobacco Lozenges Outside FDA Purview, Marketer Maintains
Allegations Ariva tobacco lozenges make implicit drug claims are without legal merit, Star Scientific maintains in response to a Dec. 18 1petition jointly filed by 18 public health organizations. The petition urges FDA to regulate the lozenges as either a food or a drug
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands